A European victory for the pharmaceutical industry
Following a preliminary reference made in the context of Seattle Genetics Inc. v Österreichisches Patentamt, the Court of Justice of the European Union has put an end to the uncertainty faced by both the innovative and the generic pharmaceutical industries regarding the duration of the effective patent protection afforded to medicinal products.